Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 427Neoplasms 376Prostatic Neoplasms 205Lung Neoplasms 194Colorectal Neoplasms 148Motor Activity 93Uterine Cervical Neoplasms 80Pancreatic Neoplasms 78Carcinoma, Non-Small-Cell Lung 75Head and Neck Neoplasms 72Brain Neoplasms 71Ovarian Neoplasms 62Carcinoma, Hepatocellular 54Rectal Neoplasms 49Neoplasm Metastasis 49Colonic Neoplasms 47Anxiety Disorders 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Depression 42Hematologic Neoplasms 41Glioblastoma 39Melanoma 37Disease 37Glioma 36Stomach Neoplasms 35Sarcoma 34Multiple Myeloma 34Lymphoma 32Pain 31Gastrointestinal Neoplasms 31

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neoplasms, Nerve Tissue × 90 days × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡